Enpowering Progression Risk of Cerebral Amyloid Angiopathy

Launched by FONDAZIONE I.R.C.C.S. ISTITUTO NEUROLOGICO CARLO BESTA · May 5, 2025

Keywords

ClinConnect Summary

The Enpowering Progression Risk of Cerebral Amyloid Angiopathy (CAA) study is looking into a condition called cerebral amyloid angiopathy, which involves the buildup of a protein in the blood vessels of the brain. This buildup can lead to serious problems like bleeding in the brain and memory issues. The goal of this study is to find better ways to diagnose CAA early and understand how to personalize treatments for patients. Researchers are particularly interested in finding specific signs and markers in patients that could help predict the disease's progression.

To be eligible for this study, participants need to be over 18 years old and have symptoms or signs of CAA, which can be confirmed by a brain MRI. However, there are some exclusions, such as individuals who cannot undergo an MRI due to medical devices, or those who are pregnant or breastfeeding. Participants in this study can expect to undergo tests and assessments that will help researchers learn more about CAA and improve future care for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients of either sex over 18 years of age;
• • patients with possible and probable symptomatic or asymptomatic CAA with or without histological demonstration (modified Boston criteria);
• • patients who have had at least one brain MRI.
• Exclusion Criteria:
• • patients who have contraindications to undergoing brain MRI (e.g., pacemaker, incompatible mechanical valves, claustrophobia);
• • patients who have contraindications to or refuse to undergo lumbar puncture;
• • patients who are unable to provide informed consent for the study due to aphasic or cognitive impairment;
• • patients who are pregnant or breastfeeding.